AIM: The aim of this study was to evaluate the utility of selected tumor markers for the detection of lung cancer recurrence during follow-up. PATIENTS AND METHODS: The study group consisted of 109 patients and 109 healthy controls. The following biomarkers were selected: Carcinoembryonic antigen; cytokeratin fragment 19; neuron-specific enolase; tissue polypeptide-specific antigen; cytokeratin fragments 8, 18 and 19; insulin-like growth factor 1; pro-gastrin-releasing peptide; and 25-hydroxyvitamin D. The biomarkers were assessed individually or using a multivariate analysis. RESULTS: Carcinoembryonic antigen [area under the receiver operating characteristics curve (AUC)=0.6857, p<0.0001] and cytokeratin fragment 19 (AUC=0.6882, p<0.0001) proved best in detecting relapse. The multivariate model indicated insulin-like growth factor 1 (p=0.0006, AUC=0.6225) as the third most useful biomarker. The multivariate model using these three markers achieved the best AUC value of 0.7730 (p=0.0050). CONCLUSION: We demonstrated that carcinoembryonic antigen and cytokeratin fragment 19 play a key role in the detection of lung cancer recurrence. A multivariate approach can increase the effectiveness of detection.

• MeSH
• adenokarcinom plic krev   patologie   chirurgie   MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• míra přežití MeSH
• nádorové biomarkery krev   MeSH
• nádory plic krev   patologie   chirurgie   MeSH
• následné studie MeSH
• nemalobuněčný karcinom plic krev   patologie   chirurgie   MeSH
• pneumektomie mortalita   MeSH
• prognóza MeSH
• prospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• spinocelulární karcinom krev   patologie   chirurgie   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

INTRODUCTION: Lung cancer is the leading cause of cancer mortality worldwide; therefore, understanding the biological or clinical role of tumor-associated antigens and autoantibodies is of eminent interest for designing antitumor immunotherapeutic strategies. METHODS: Here we prospectively analyzed the serum frequencies of New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human epidermal growth factor 2/neu, and melanoma-associated antigen A4 (MAGE-A4) antibodies and expression of the corresponding antigens in tumors of 121 patients with NSCLC undergoing an operation without prior neoadjuvant chemotherapy and compared them with those in 57 control age-matched patients with no history of a malignant disease. RESULTS: We found that only antibodies specific for NY-ESO-1 (19.8% [n = 24 of 121]) were significantly increased in the group of patients with NSCLC compared with in the controls. NY-ESO-1 seropositivity was significantly positively associated with an active smoking history in patients with NSCLC but not in smokers from the control group. In tumors, the frequency of NY-ESO-1 mRNA expression was 6.3% (in four of 64 patients), the frequency of human epidermal growth factor 2/neu (HER 2/neu) expression was 11.9% (five of 42), and the frequency of MAGE-A4 expression was 35.1% (20 of 57). MAGE-A4 expression in tumors correlated with smoking status and male sex in patients with NSCLC. Patients with squamous cell carcinoma displayed higher expression of NY-ESO-1 and MAGE-A4 in tumors than did patients with adenocarcinoma. On the other hand, 94.7% of nonsmoking patients in our study had adenocarcinoma (of whom 73.7% were women). CONCLUSION: These results confirm the reported high immunogenicity of NY-ESO-1 and suggest that a smoking-induced chronic inflammatory state might potentiate the development of NY-ESO-1-specific immune responses. Moreover, smoking might contribute to the expression of other cancer/testis antigens such as MAGE-A4 at early stages of NSCLC development.

• MeSH
• adenokarcinom krev   etiologie   patologie   MeSH
• antigeny nádorové krev   imunologie   MeSH
• dospělí MeSH
• kouření škodlivé účinky   MeSH
• lidé středního věku MeSH
• lidé MeSH
• membránové proteiny krev   imunologie   MeSH
• nádorové biomarkery krev   MeSH
• nádorové proteiny krev   MeSH
• nádory plic krev   etiologie   patologie   MeSH
• následné studie MeSH
• nemalobuněčný karcinom plic krev   etiologie   patologie   MeSH
• prognóza MeSH
• prospektivní studie MeSH
• receptor erbB-2 krev   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• spinocelulární karcinom krev   etiologie   patologie   MeSH
• staging nádorů MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH

BACKGROUND/AIM: Head and neck squamous cell carcinoma (HNSCC) includes tumors of various anatomical sites sharing multifactorial etiopathogenesis and generally dismal response to conventional treatment. The objective of this study was to determine the clinical significance of serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) in HNSCC. PATIENTS AND METHODS: A total of 46 patients, with histologically-confirmed diagnosis of HNSCC (21 oropharyngeal, 21 laryngeal, and 4 hypopharyngeal cancers) were enrolled in this study. IGF-1 and IGFBP-3 serum levels were measured by an immunoradiometric assay using commercial kits. The adjustment of serum levels at 60 years of age was performed. RESULTS: Significant differences were found in IGF-1 serum concentrations between patients with p16 positive and p16 negative HNSCC (p=0.0062), with higher IGF-1 levels in p16 positive tumors, between low-grade and high-grade cancers (p=0.0323) only in larynx, with elevated IGF-1 concentrations associated with high-grade and between recurrent and non-recurrent HNSCC (p=0.0354), with lower IGF-1 levels in recurrent tumors. CONCLUSION: The conflicting results of this study may reflect some abnormality of IGF axis regulation in HNSCC, as well as the influence of other etiological factors (e.g. smoking, HPV infection).

• MeSH
• IGFBP-3 krev   MeSH
• imunohistochemie MeSH
• imunoradiometrická analýza MeSH
• inhibitor p16 cyklin-dependentní kinasy analýza   MeSH
• insulinu podobný růstový faktor I analýza   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lokální recidiva nádoru MeSH
• nádorové biomarkery analýza   krev   MeSH
• nádory hlavy a krku krev   chemie   patologie   MeSH
• prediktivní hodnota testů MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• spinocelulární karcinom krev   chemie   patologie   MeSH
• stupeň nádoru MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• srovnávací studie MeSH

BACKGROUND Abnormal metabolism of fatty acids (FA) is considered to play a role in human cancers, including esophageal cancer (EC). Nevertheless, there have been only a few studies dealing with the influence of the chemotherapy or radiotherapy on the plasma FA profiles. In this work we compared FA in plasma phosphatidylcholine (PC) of the patients with squamous EC and healthy subjects and investigated changes in the FA spectrum during neoadjuvant chemoradiotherapy (CRT). MATERIAL AND METHODS Forty-two men with squamous EC were compared with age-matched healthy controls. The EC group was subjected to concurrent neoadjuvant CRT. We analyzed FA in plasma PC before and after CRT. RESULTS The EC group was characterized by increased levels of both saturated and monounsaturated FA, associated with an increased index of SCD1 (stearoyl-CoA desaturase-1). Moreover, decreased levels of linoleic acid and total polyunsaturated FA (PUFA) n-6 were found in EC patients. The CRT was accompanied by increased docosahexaenoic acid and total PUFA n-3 content in plasma PC, concurrently with the decrease of estimated activity of SCD1. CONCLUSIONS We found that patients with EC had altered FA profile in plasma PC, which could be related to abnormal FA metabolism in cancer (e.g., altered synthesis de novo, b-oxidation, desaturation, and elongation). The described changes in FA profiles during CRT could be involved in favorable functioning of CRT. Further studies investigating the plasma FA compositions and their changes due to CRT in EC patients are warranted.

• MeSH
• chemoradioterapie MeSH
• dospělí MeSH
• fosfatidylcholiny krev   MeSH
• kyseliny mastné mononenasycené krev   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mastné kyseliny krev   MeSH
• metabolismus lipidů fyziologie   MeSH
• nádory jícnu krev   farmakoterapie   radioterapie   terapie   MeSH
• neoadjuvantní terapie MeSH
• spinocelulární karcinom krev   farmakoterapie   radioterapie   terapie   MeSH
• stearyl-CoA-desaturasa metabolismus   MeSH
• studie případů a kontrol MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. RESULTS: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib.

• MeSH
• adenokarcinom krev   farmakoterapie   mortalita   MeSH
• antigeny nádorové krev   MeSH
• chinazoliny terapeutické užití   MeSH
• dospělí MeSH
• erbB receptory antagonisté a inhibitory   genetika   MeSH
• inhibitory proteinkinas terapeutické užití   MeSH
• karcinoembryonální antigen krev   MeSH
• keratin-19 krev   MeSH
• lidé středního věku MeSH
• lidé MeSH
• míra přežití MeSH
• mutace genetika   MeSH
• nádorové biomarkery krev   MeSH
• nádory plic krev   farmakoterapie   mortalita   MeSH
• následné studie MeSH
• nemalobuněčný karcinom plic krev   farmakoterapie   mortalita   MeSH
• prognóza MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• spinocelulární karcinom krev   farmakoterapie   mortalita   MeSH
• staging nádorů MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Východiská: Hypoxia lokálne pokročilých karcinómov hlavy a krku je jednou z hlavných príčin ich rádiorezistencie, ktorá sa klinicky manifestuje perzistenciou reziduálnej nádorovej choroby po liečbe rádioterapiou. Detekcia nádorovej hypoxie teda môže byť dôležitým prediktorom efektivity liečby. Karboanhydráza IX (carbonic anhydrase IX – CA IX) je proteín, kódovaný rovnomenným génom, ktorého expresia sa v nádorových tkanivách za hypoxických podmienok zvyšuje. CA IX preto predstavuje endogénny marker nádorovej hypoxie, identifikovateľný v nádorových tkanivách a jeho rozpustnú extracelulárnu doménu je možné detekovať aj v telesných tekutinách pacienta. Primárnym cieľom tejto štúdie bolo zistiť, či existuje korelácia medzi sérovou hladinou CA IX a reziduálnou nádorovou chorobou po liečbe. Sekundárnym cieľom bolo zistiť, ako sa mení sérová hladina CA IX počas frakcionovanej rádioterapie. Materiál a metódy: Táto prospektívna monocentrická klinická štúdia hodnotila súbor 30 pacientov s lokálne pokročilými skvamocelulárnymi karcinómami hlavy a krku, liečených rádioterapiou alebo konkomitantnou chemorádioterapiou s kuratívnym zámerom. Sérová koncentrácia rozpustnej formy CA IX sa vyšetrovala z venóznej krvi pomocou sendvičovej enzýmovej imunoanalýzy (ELISA) pred zahájením rádioterapie, v polovici rádioterapie, pri skončení rádioterapie a šesť týždňov po jej ukončení. Výsledky: Zistili sme výraznú variabilitu nameraných hladín CA IX v sledovanej populácii v rozsahu 0–1 696 pg/ml. Významné zmeny v strednej hodnote koncentrácie CA IX sme v priebehu rádioterapie a po nej nezistili. U 11 pacientov (36,7 %) sa liečbou dosiahla kompletná remisia ochorenia. U týchto pacientov sme zaznamenali v priemere nižšie predliečebné hodnoty CA IX v porovnaní s pacientmi s perzistenciou reziduálnej nádorovej choroby (37,57 vs 77,47; p = 0,154). Záver: Naše výsledky ukazujú, že sérová hladina CA IX sa u pacientov s lokálne pokročilými nádormi hlavy a krku v priebehu frakcionovanej rádioterapie významne nemení. Zistený vzťah medzi sérovou hladinou CA IX a reziduálnou nádorovou chorobou po rádioterapii je potrebné potvrdiť na väčšom súbore pacientov.

Background: Hypoxia of locally advanced head and neck cancers is one of the main causes of their radiation resistance that presents clinically as a persistence of residual tumor disease after radiation therapy. Therefore, detection of tumor hypoxia could be an important predictor of treatment efficacy. Carbonic anhydrase IX (CA IX) is a protein, coded by a homonymous gene, the expression of which increases in tumor tissues at hypoxic conditions. Hence, CA IX represents an endogenic marker of tumor hypoxia, identifiable in tumor tissues, and its soluble extracellular domain can also be detected in body fluids of the patient. The primary endpoint of this study was to explore whether a correlation exists between CA IX serum level and the residual tumor disease after therapy. The secondary endpoint was to find out how the serum concentration of CA IX changes during the course of fractionated radiation therapy. Materials and Methods: The presented prospective monocentric clinical study evaluated a population of 30 patients with locally advanced squamous cell head and neck cancers, treated by radiation therapy or concurrent chemo‑radiation therapy with a curative intent. The serum concentration of the soluble form of CA IX was examined from a venous blood sample, using sandwich enzyme‑linked immunosorbent assay (ELISA). The blood samples were obtained before the treatment initiation, in the middle of radiation therapy, at the time of finishing radiation therapy and six weeks after the treatment completion. Results: We found a substantial variability in the CA IX levels measured in the examined population, ranging 0–1,696 pg/ml. We found no significant changes in the mean value of CA IX concentration during the course of radiation therapy and after the treatment completion. In 11 patients (36.7%), the treatment resulted in complete remission of the disease. In these patients, lower average pre‑treatment levels of CA IX were noted when compared to patients with persistence of residual tumor disease (37.57 vs 77.47; p = 0.154). Conclusion: The results indicate that serum level of CA IX in patients with locally advanced head and neck cancers does not change significantly during the course of fractionated radiation therapy. The relation between CA IX serum level and residual tumor disease after radiation therapy requires verification on a larger population of patients. Key words: head and neck cancer – hypoxia – carbonic anhydrase IX – radiation therapy – residual tumor The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers. Submitted: 10. 2. 2014 Accepted: 4. 3. 2014

• Klíčová slova
• karboanhydráza IX, radiorezistence,
• MeSH
• ELISA MeSH
• frakcionace dávky záření MeSH
• hypoxie buňky * účinky záření   MeSH
• karboanhydrasy * krev   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádorové biomarkery * krev   MeSH
• nádorové proteiny * krev   MeSH
• nádory hlavy a krku * enzymologie   krev   metabolismus   radioterapie   MeSH
• prospektivní studie MeSH
• reziduální nádor krev   MeSH
• senioři MeSH
• spinocelulární karcinom enzymologie   krev   metabolismus   radioterapie   MeSH
• statistika jako téma MeSH
• transport proteinů MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH

BACKGROUND: The convergence of nutritional, genetic, and inflammatory factors plays a significant role in the pathophysiology of squamous cell esophageal cancer (SCEC). The parameters of inflammation, indices of nutritional status, and adipocyte-derived hormones such as leptin, adiponectin, and resistin have been shown to be prognostic factors in some gastrointestinal and pancreatic cancers. MATERIAL/METHODS: Forty-two patients with SCEC were subjected to a multimodal regimen of concurrent neoadjuvant chemoradiotherapy (CRT) followed by surgery. We retrospectively analyzed the impact of pretreatment values of serum leptin, adiponectin, resistin, soluble leptin receptor, C-reactive protein, TNF alpha, leukocytes, and indices of nutritional status (BMI, plasma total protein, albumin, cholesterol, and triacylglycerols) on overall survival (OS). RESULTS: Univariate analysis revealed significant a negative correlation between OS and serum adiponectin (p=0.027), and a positive relationship was found between serum albumin (p=0.002), cholesterol (p=0.049) level, and OS. In multivariate analysis, only the trend (p=0.086) for negative serum adiponectin association with the OS was observed. CONCLUSIONS: In men with SCEC treated by neoadjuvant concurrent CRT and esophagectomy, high pretreatment level of serum adiponectin was associated with shorter OS while the serum albumin and cholesterol were associated with longer OS.

• MeSH
• adiponektin krev   MeSH
• analýza přežití MeSH
• chemoradioterapie * MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• multivariační analýza MeSH
• nádory jícnu krev   chirurgie   terapie   MeSH
• pilotní projekty MeSH
• předoperační péče * MeSH
• proporcionální rizikové modely MeSH
• senioři MeSH
• spinocelulární karcinom krev   chirurgie   terapie   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

BACKGROUND: Head and neck squamous cell cancer (HNSCC) includes tumors of various anatomical sites sharing common etiological factors. Serum levels of MMP1, MMP2, and MMP9 were analyzed in patients with oropharyngeal, laryngeal, and hypopharyngeal carcinomas in an effort to elucidate the pathobiology and in order to find useful biomarkers of site-specific HNSCC. PATIENTS AND METHODS: The study group comprised of 46 patients with HNSCC (21 with oropharyngeal, 21 with laryngeal and 4 with hypopharyngeal cancer). Serum levels of MMP1, -2, and -9 were determined by the MAGPIX multiplex method. P16 protein was detected by immunohistochemistry. Serum levels of matrix metalloproteinases (MMPs) were correlated with clinicopathological features of carcinomas and were compared with respect to tumor site. RESULTS: Significant correlations were confirmed between p16 positivity and oropharyngeal cancer, MMP1 and p16 positivity, and recurrence and smoking. Statistically significant differences in serum levels of MMPs between cancer of different locations were not found. CONCLUSION: MMP1 expression is significantly affected by smoking habit and by p16 and might mediate etiopathogenetical process in cancerogenesis of HNSCC. Our pilot study did not establish any utility of MMP1, -2, or -9 in clinical practice as diagnostic/prognostic markers.

• MeSH
• alkoholismus MeSH
• imunohistochemie MeSH
• inhibitor p16 cyklin-dependentní kinasy biosyntéza   genetika   MeSH
• kouření škodlivé účinky   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lokální recidiva nádoru MeSH
• matrixová metaloproteinasa 1 krev   MeSH
• matrixová metaloproteinasa 2 krev   MeSH
• matrixová metaloproteinasa 9 krev   MeSH
• nádorové biomarkery krev   MeSH
• nádory hlavy a krku krev   MeSH
• nádory hrtanu krev   MeSH
• nádory hypofaryngu krev   MeSH
• nádory orofaryngu krev   MeSH
• pilotní projekty MeSH
• předoperační období MeSH
• prognóza MeSH
• regulace genové exprese u nádorů MeSH
• spinocelulární karcinom krev   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

With the increasing demand for noninvasive approaches in monitoring head and neck cancer, circulating nucleic acids have been shown to be a promising tool. We focused on the global transcriptome of serum samples of head and neck squamous cell carcinoma (HNSCC) patients in comparison with healthy individuals. We compared gene expression patterns of 36 samples. Twenty-four participants including 16 HNSCC patients (from 12 patients we obtained blood samples 1 year posttreatment) and 8 control subjects were recruited. The Illumina HumanWG-6 v3 Expression BeadChip was used to profile and identify the differences in serum mRNA transcriptomes. We found 159 genes to be significantly changed (Storey's P value <0.05) between normal and cancer serum specimens regardless of factors including p53 and B-cell lymphoma family members (Bcl-2, Bcl-XL). In contrast, there was no difference in gene expression between samples obtained before and after surgery in cancer patients. We suggest that microarray analysis of serum cRNA in patients with HNSCC should be suitable for refinement of early stage diagnosis of disease that can be important for development of new personalized strategies in diagnosis and treatment of tumours but is not suitable for monitoring further development of disease.

• MeSH
• analýza hlavních komponent MeSH
• apoptóza genetika   MeSH
• demografie MeSH
• dospělí MeSH
• genom lidský genetika   MeSH
• lidé středního věku MeSH
• lidé MeSH
• messenger RNA krev   genetika   MeSH
• mikročipová analýza * MeSH
• nádorový supresorový protein p53 metabolismus   MeSH
• nádory hlavy a krku krev   genetika   patologie   MeSH
• regulace genové exprese u nádorů MeSH
• senioři MeSH
• signální transdukce genetika   MeSH
• spinocelulární karcinom krev   genetika   patologie   MeSH
• stanovení celkové genové exprese MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

BACKGROUND: Human papillomaviruses (HPVs) have been proved as one of the etiological factors of oropharyngeal squamous cell carcinoma (OPSCC). Patients with tumors of viral etiology have a lower recurrence rate and better prognosis. OPSCC is linked to an alteration in the immune system. Only a limited number of studies have correlated both the immunological parameters and HPV status with patient prognosis. The aim of this study was to determine whether HPV infection and the immunological status influence patient prognosis individually or in concurrence. MATERIAL AND METHODS: Sixty patients with oral and oropharyngeal carcinomas were enrolled. They were divided into HPV-positive and HPV-negative groups based on the expression of HPV 16 E6 mRNA. Basic lymphocyte subpopulations were determined in the peripheral blood by means of flow cytometry. RESULTS: Significantly better disease-specific survival (DSS) was observed in patients with HPV-positive tumors. Nodal status, tumor grade, recurrence, and CD8+/Tregs ratio were identified as factors influencing DSS. A higher level of Tregs and a lower ratio of CD8/Tregs influenced overall survival (OS) independently of HPV status and age. Patients with HPV-positive tumors and high levels of Tregs survived significantly better than patients from the other groups. CONCLUSION: Better survival is associated with HPV positivity and elevated Tregs levels. Our data suggest that HPV infection and Tregs do not influence patient prognosis in concurrence.

• MeSH
• analýza přežití MeSH
• biologické markery krev   MeSH
• buňky NK imunologie   MeSH
• demografie MeSH
• inhibitor p16 cyklin-dependentní kinasy metabolismus   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory orofaryngu krev   epidemiologie   imunologie   virologie   MeSH
• Papillomaviridae fyziologie   MeSH
• prognóza MeSH
• proporcionální rizikové modely MeSH
• regresní analýza MeSH
• regulační T-lymfocyty imunologie   MeSH
• spinocelulární karcinom krev   epidemiologie   imunologie   virologie   MeSH
• stupeň nádoru MeSH
• věkové faktory MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH